MARKET

AUTL

AUTL

AUTOLUS THERAPEUTICS PLC
NASDAQ
1.680
+0.040
+2.44%
After Hours: 1.700 +0.02 +1.19% 16:53 12/24 EST
OPEN
1.650
PREV CLOSE
1.640
HIGH
1.690
LOW
1.630
VOLUME
726.45K
TURNOVER
--
52 WEEK HIGH
2.800
52 WEEK LOW
1.105
MARKET CAP
447.12M
P/E (TTM)
-1.9891
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at AUTL last week (1215-1219)?
Weekly Report · 2d ago
Autolus Therapeutics plc's (NASDAQ:AUTL) Shares Bounce 28% But Its Business Still Trails The Industry
Simply Wall St · 4d ago
Weekly Report: what happened at AUTL last week (1208-1212)?
Weekly Report · 12/15 09:48
Autolus Therapeutics Price Target Maintained With a $10.00/Share by Needham
Dow Jones · 12/12 11:12
Analysts Offer Insights on Healthcare Companies: Autolus Therapeutics (AUTL) and Tenaya Therapeutics (TNYA)
TipRanks · 12/12 11:10
Wells Fargo Sticks to Its Buy Rating for Autolus Therapeutics (AUTL)
TipRanks · 12/09 11:56
Analysts Offer Insights on Healthcare Companies: Kura Oncology (KURA) and Autolus Therapeutics (AUTL)
TipRanks · 12/09 11:50
Autolus Reveals Latest Phase I Findings For Obe-cel In Hard-to-Treat Lupus
NASDAQ · 12/09 10:45
More
About AUTL
Autolus Therapeutics plc is a United Kingdom-based early commercial-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. The Company has an approved commercial product, AUCATZYL, for the treatment of adult patients with r/r B-ALL. Using a suite of proprietary and modular T cell programming technologies, it is also developing five programs in seven hematological and solid tumor indications and one autoimmune indication. It is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and eliminate these cells. Its product pipeline includes obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting TRBC 1 and TRBC 2.

Webull offers Autolus Therapeutics PLC (ADR) stock information, including NASDAQ: AUTL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AUTL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AUTL stock methods without spending real money on the virtual paper trading platform.